vs

Side-by-side financial comparison of CSW INDUSTRIALS, INC. (CSW) and Harmony Biosciences Holdings, Inc. (HRMY). Click either name above to swap in a different company.

Harmony Biosciences Holdings, Inc. is the larger business by last-quarter revenue ($243.8M vs $233.0M, roughly 1.0× CSW INDUSTRIALS, INC.). Harmony Biosciences Holdings, Inc. runs the higher net margin — 9.2% vs 4.4%, a 4.8% gap on every dollar of revenue. On growth, Harmony Biosciences Holdings, Inc. posted the faster year-over-year revenue change (21.1% vs 20.3%). Harmony Biosciences Holdings, Inc. produced more free cash flow last quarter ($126.0M vs $22.7M). Over the past eight quarters, Harmony Biosciences Holdings, Inc.'s revenue compounded faster (25.6% CAGR vs 5.1%).

Harmony Biosciences Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for rare neurological and central nervous system disorders. Its primary market is the United States, with its core product serving patients living with narcolepsy and other sleep-related CNS conditions across adult and pediatric segments.

CSW vs HRMY — Head-to-Head

Bigger by revenue
HRMY
HRMY
1.0× larger
HRMY
$243.8M
$233.0M
CSW
Growing faster (revenue YoY)
HRMY
HRMY
+0.8% gap
HRMY
21.1%
20.3%
CSW
Higher net margin
HRMY
HRMY
4.8% more per $
HRMY
9.2%
4.4%
CSW
More free cash flow
HRMY
HRMY
$103.3M more FCF
HRMY
$126.0M
$22.7M
CSW
Faster 2-yr revenue CAGR
HRMY
HRMY
Annualised
HRMY
25.6%
5.1%
CSW

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
CSW
CSW
HRMY
HRMY
Revenue
$233.0M
$243.8M
Net Profit
$10.3M
$22.5M
Gross Margin
39.7%
71.9%
Operating Margin
7.4%
15.8%
Net Margin
4.4%
9.2%
Revenue YoY
20.3%
21.1%
Net Profit YoY
-61.9%
-54.6%
EPS (diluted)
$0.62
$0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CSW
CSW
HRMY
HRMY
Q4 25
$233.0M
$243.8M
Q3 25
$277.0M
$239.5M
Q2 25
$263.6M
$200.5M
Q1 25
$230.5M
$184.7M
Q4 24
$193.6M
$201.3M
Q3 24
$227.9M
$186.0M
Q2 24
$226.2M
$172.8M
Q1 24
$210.9M
$154.6M
Net Profit
CSW
CSW
HRMY
HRMY
Q4 25
$10.3M
$22.5M
Q3 25
$40.7M
$50.9M
Q2 25
$40.9M
$39.8M
Q1 25
$35.1M
$45.6M
Q4 24
$26.9M
$49.5M
Q3 24
$36.1M
$46.1M
Q2 24
$38.6M
$11.6M
Q1 24
$31.8M
$38.3M
Gross Margin
CSW
CSW
HRMY
HRMY
Q4 25
39.7%
71.9%
Q3 25
43.0%
75.1%
Q2 25
43.8%
81.0%
Q1 25
44.2%
82.7%
Q4 24
41.4%
73.0%
Q3 24
45.6%
77.0%
Q2 24
47.5%
81.4%
Q1 24
44.4%
82.2%
Operating Margin
CSW
CSW
HRMY
HRMY
Q4 25
7.4%
15.8%
Q3 25
20.5%
27.3%
Q2 25
20.8%
24.0%
Q1 25
19.5%
30.4%
Q4 24
15.3%
27.7%
Q3 24
22.6%
33.2%
Q2 24
24.3%
12.4%
Q1 24
21.0%
33.7%
Net Margin
CSW
CSW
HRMY
HRMY
Q4 25
4.4%
9.2%
Q3 25
14.7%
21.2%
Q2 25
15.5%
19.8%
Q1 25
15.2%
24.7%
Q4 24
13.9%
24.6%
Q3 24
15.8%
24.8%
Q2 24
17.1%
6.7%
Q1 24
15.1%
24.8%
EPS (diluted)
CSW
CSW
HRMY
HRMY
Q4 25
$0.62
$0.38
Q3 25
$2.41
$0.87
Q2 25
$2.43
$0.68
Q1 25
$2.05
$0.78
Q4 24
$1.60
$0.85
Q3 24
$2.26
$0.79
Q2 24
$2.47
$0.20
Q1 24
$2.03
$0.67

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CSW
CSW
HRMY
HRMY
Cash + ST InvestmentsLiquidity on hand
$40.2M
$775.3M
Total DebtLower is stronger
$163.7M
Stockholders' EquityBook value
$1.1B
$870.2M
Total Assets
$2.3B
$1.3B
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CSW
CSW
HRMY
HRMY
Q4 25
$40.2M
$775.3M
Q3 25
$31.5M
$672.6M
Q2 25
$38.0M
$565.3M
Q1 25
$225.8M
$507.0M
Q4 24
$213.8M
$467.2M
Q3 24
$273.2M
$410.5M
Q2 24
$18.9M
$346.9M
Q1 24
$22.2M
$372.4M
Total Debt
CSW
CSW
HRMY
HRMY
Q4 25
$163.7M
Q3 25
$168.5M
Q2 25
$172.1M
Q1 25
$800.1M
$175.7M
Q4 24
$179.3M
Q3 24
$182.8M
Q2 24
$186.4M
Q1 24
$166.0M
$190.0M
Stockholders' Equity
CSW
CSW
HRMY
HRMY
Q4 25
$1.1B
$870.2M
Q3 25
$1.1B
$835.1M
Q2 25
$1.1B
$773.1M
Q1 25
$1.1B
$720.5M
Q4 24
$1.0B
$659.2M
Q3 24
$1.0B
$596.8M
Q2 24
$650.2M
$538.6M
Q1 24
$615.7M
$515.4M
Total Assets
CSW
CSW
HRMY
HRMY
Q4 25
$2.3B
$1.3B
Q3 25
$1.5B
$1.2B
Q2 25
$1.5B
$1.1B
Q1 25
$1.4B
$1.1B
Q4 24
$1.4B
$999.2M
Q3 24
$1.4B
$928.1M
Q2 24
$1.1B
$858.4M
Q1 24
$1.0B
$847.0M
Debt / Equity
CSW
CSW
HRMY
HRMY
Q4 25
0.19×
Q3 25
0.20×
Q2 25
0.22×
Q1 25
0.75×
0.24×
Q4 24
0.27×
Q3 24
0.31×
Q2 24
0.35×
Q1 24
0.27×
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CSW
CSW
HRMY
HRMY
Operating Cash FlowLast quarter
$28.9M
$126.2M
Free Cash FlowOCF − Capex
$22.7M
$126.0M
FCF MarginFCF / Revenue
9.8%
51.7%
Capex IntensityCapex / Revenue
2.6%
0.0%
Cash ConversionOCF / Net Profit
2.81×
5.61×
TTM Free Cash FlowTrailing 4 quarters
$162.0M
$347.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CSW
CSW
HRMY
HRMY
Q4 25
$28.9M
$126.2M
Q3 25
$61.8M
$108.7M
Q2 25
$60.6M
$79.3M
Q1 25
$27.3M
$34.0M
Q4 24
$11.6M
$75.6M
Q3 24
$66.8M
$70.5M
Q2 24
$62.7M
$42.6M
Q1 24
$22.4M
$31.1M
Free Cash Flow
CSW
CSW
HRMY
HRMY
Q4 25
$22.7M
$126.0M
Q3 25
$58.7M
$108.7M
Q2 25
$57.7M
$79.3M
Q1 25
$22.8M
$33.9M
Q4 24
$8.5M
$75.0M
Q3 24
$61.3M
$70.5M
Q2 24
$59.6M
$42.0M
Q1 24
$17.5M
$31.1M
FCF Margin
CSW
CSW
HRMY
HRMY
Q4 25
9.8%
51.7%
Q3 25
21.2%
45.4%
Q2 25
21.9%
39.6%
Q1 25
9.9%
18.3%
Q4 24
4.4%
37.3%
Q3 24
26.9%
37.9%
Q2 24
26.3%
24.3%
Q1 24
8.3%
20.1%
Capex Intensity
CSW
CSW
HRMY
HRMY
Q4 25
2.6%
0.0%
Q3 25
1.1%
0.0%
Q2 25
1.1%
0.0%
Q1 25
2.0%
0.1%
Q4 24
1.6%
0.3%
Q3 24
2.4%
0.0%
Q2 24
1.4%
0.4%
Q1 24
2.3%
0.0%
Cash Conversion
CSW
CSW
HRMY
HRMY
Q4 25
2.81×
5.61×
Q3 25
1.52×
2.14×
Q2 25
1.48×
1.99×
Q1 25
0.78×
0.75×
Q4 24
0.43×
1.53×
Q3 24
1.85×
1.53×
Q2 24
1.62×
3.68×
Q1 24
0.71×
0.81×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CSW
CSW

Contractor Solutions Segment$166.3M71%
Specialized Reliability Solutions Segment$38.2M16%
Engineered Building Solutions Segment$28.5M12%

HRMY
HRMY

Segment breakdown not available.

Related Comparisons